Stocktoria
NovoCure Ltd NVCR
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2015-10-01
NovoCure Ltd financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M | $494.4M | $351.3M | $248.1M | $177.0M | $82.9M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M | $387.9M | $262.7M | $168.0M | $121.4M | $36.6M |
| R&D expense | $224.5M | $209.6M | $223.1M | $206.1M | $201.3M | $132.0M | $79.0M | $50.6M | $38.1M | $41.5M |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M | -$44.3M | $30.4M | -$914,000 | -$33.7M | -$39.3M | -$115.3M |
| Interest expense | $22.2M | $11.7M | $4.9M | $8.1M | $8.8M | $18.1M | $14.6M | $16.9M | $11.7M | $7.3M |
| Income tax | -$23,000 | $37.5M | $15.3M | $10.7M | $6.3M | -$1.7M | -$1.6M | $17.6M | $13.2M | $10.4M |
| Net income | -$136.2M | -$168.6M | -$207.0M | -$92.5M | -$58.4M | $19.8M | -$7.2M | -$63.6M | -$61.7M | -$131.8M |
| EPS (diluted) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.18 | $-0.07 | $-0.69 | — | — |
| Operating cash flow | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M | $99.1M | $26.6M | -$1.9M | -$33.1M | -$107.6M |
| Free cash flow | -$75.7M | -$69.2M | -$100.4M | $9.4M | $58.6M | $84.2M | $16.1M | -$8.6M | -$40.5M | -$113.3M |
| Cash & equivalents | $93.5M | $163.8M | $240.8M | $115.3M | $208.8M | $234.7M | $177.3M | $140.6M | $78.6M | $99.8M |
| Inventory | $41.1M | $35.1M | $38.2M | $29.4M | $24.4M | $27.4M | $23.7M | $22.6M | $22.0M | $25.5M |
| Total assets | $804.3M | $1.2B | $1.1B | $1.2B | $1.1B | $1.1B | $479.4M | $339.8M | $265.3M | $282.1M |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M | $575.5M | $261.7M | $227.5M | $151.7M | $139.7M |
| Shareholders' equity | $340.5M | $360.2M | $362.5M | $441.2M | $410.5M | $476.5M | $217.8M | $112.3M | $113.6M | $142.3M |
Growth · year-over-year · Revenue CAGR 25.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +8.3% | +18.8% | -5.3% | +0.5% | +8.2% | +40.7% | +41.6% | +40.1% | +113.6% | +150.5% |
| Net income growth | — | — | — | — | -394.6% | — | — | — | — | — |
| EPS growth | — | — | — | — | -411.1% | — | — | — | — | — |
| Free cash flow growth | — | — | -1165.0% | -83.9% | -30.4% | +421.7% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.